Clinical Implications of New Drugs for Lowering Plasma Cholesterol Concentrations
- 1 February 1991
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 41 (2), 151-160
- https://doi.org/10.2165/00003495-199141020-00001
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia: The finnish multicenter studyThe American Journal of Cardiology, 1988
- Efficacy and long-term adverse effect pattern of lovastatinThe American Journal of Cardiology, 1988
- Discovery, biochemistry and biology of lovastatinThe American Journal of Cardiology, 1988
- HMG-CoA Reductase Inhibitors for Treatment of HypercholesterolemiaNew England Journal of Medicine, 1988
- Lovastatin for Lowering Cholesterol Levels in Non-Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1988
- Lipid-Lowering DrugsDrugs, 1987
- CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal speciesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1986
- Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemiaThe American Journal of Cardiology, 1986
- Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia.Journal of Clinical Investigation, 1984
- Effects of an Inhibitor of 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase on Serum Lipoproteins and Ubiquinone-10 Levels in Patients with Familial HypercholesterolemiaNew England Journal of Medicine, 1981